HSA
KNSA icon

Hussman Strategic Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Hussman Strategic Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,000
Closed -$1.01M – 284
2026
Q1 		$1.01M Buy
+21,000
New +$930K 0.22% 192
2024
Q4 		– Sell
-84,000
Closed -$2.1M – 273
2024
Q3 		$2.1M Sell
84,000
-63,000
-43% -$1.53M 0.52% 87
2024
Q2 		$2.74M Sell
147,000
-10,500
-7% -$197K 0.76% 39
2024
Q1 		$3.11M Buy
+157,500
New +$3.08M 0.72% 51

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Hussman Strategic Advisors's KNSA Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 21,000 shares — an estimated $1.01M sold.

Hussman Strategic Advisors first reported a position in KNSA in Q1 2024 and held it in 4 quarters. The position peaked at $3.11M in Q1 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 21,000 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Hussman Strategic Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Hussman Strategic Advisors's Kiniksa Pharmaceuticals position peaked at $3.11M in Q1 2024.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.